AME 527

Drug Profile

AME 527

Latest Information Update: 26 Mar 2009

Price : $50

At a glance

  • Originator Applied Molecular Evolution
  • Class Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 24 Nov 2005 Phase-I/II clinical trials in Rheumatoid arthritis in USA (unspecified route)
  • 24 Nov 2005 Data presented at the 69th Annual Scientific Meeting of the American College of Rheumatology and the 40th Annual Meeting of the Association of Rheumatology Health Professionals (ACR/ARHP-2005) have been added to the adverse events and Rheumatic disease pharmacodynamics sections
  • 16 Feb 2004 Applied Molecular Evolution has been acquired by Eli Lilly
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top